Abstract |
Bone marrow transplantation (BMT) from matched sibling donors has been useful for the treatment of acute lymphoblastic leukaemia in children with a poor prognosis but is not available to more than two-thirds of patients who do not have a matched allogeneic donor. This study was undertaken to assess one strategy of marrow graft rejection prevention when alternative marrow sources such as HLA-phenoidentical unrelated volunteers and HLA-partially incompatible relatives were used. Results have been compared with two matched groups of children with the same risks factors and disease status who underwent HLA-genoidentical or autologous BMT. The conditioning regimen was the same for the three groups of patients; in the study group anti-LFA-1 and anti-CD2 monoclonal antibodies combined with T-cell depletion of the marrow was added to prevent graft rejection and graft-versus-host disease. Nineteen patients were included and followed for a median of 25 months (14 months to 3 years). Bone marrow engraftment occurred in 83% of the evaluable patients. Post- transplantation infectious diseases were the most frequent causes of death in the study group, occurring in 31% of patients. No fatal infections occurred in the two control groups. Post- transplantation relapse of leukaemia occurred in 26% of study group's patients, in 58% of autologous BMT control group's patients and 5% of HLA-genoidentical allogeneic group's patients. The event-free survival was 83% in the HLA-genoidentical control group, and 30% and 24% in the study group and in the autologous control group, respectively. In conclusion, a high rate of engraftment was achieved by the use of anti-LFA-1 and anti CD2 antibodies. Occurrence of a long-lasting immunodeficiency, however, led to a high incidence of lethal infections and relapses. Combined approaches are therefore to be investigated accelerating immune reconstitution after transplantations of T-depleted HLA partially incompatible marrow.
|
Authors | M Cavazzana-Calvo, P Bordigoni, G Michel, H Esperou, G Souillet, T Leblanc, J L Stephan, J P Vannier, F Mechinaud, J Reiffers, E Vilmer, J Landman-Parker, M Benkerrou, A Baruchel, J Pico, F Bernaudin, C Bergeron, E Plouvier, C Thomas, J Wijdenes, B Lacour, S Blanche, A Fischer |
Journal | British journal of haematology
(Br J Haematol)
Vol. 93
Issue 1
Pg. 131-8
(Apr 1996)
ISSN: 0007-1048 [Print] England |
PMID | 8611446
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- CD2 Antigens
- Lymphocyte Function-Associated Antigen-1
|
Topics |
- Adolescent
- Antibodies, Monoclonal
(therapeutic use)
- Bone Marrow Transplantation
- CD2 Antigens
(immunology)
- Child
- Child, Preschool
- Female
- Graft Rejection
(prevention & control)
- Graft vs Host Disease
(prevention & control)
- Histocompatibility
- Histocompatibility Testing
- Humans
- Lymphocyte Function-Associated Antigen-1
(immunology)
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(therapy)
|